Likes2Trade

$itrm the process in the Irish High Court is signaling we have an offer. Are we to believe it’s less than the $~70M all in debt? Would be absolutely shocking

$ITRM 10M in volume. stair-step accumulation pattern with multiple consolidations and higher lows, rather than a typical one-time spike and fade. Trading aint for the weak, this resolve T- April 13th will shock all that ever touched this stock. Yet, be so obvious in hindsight

@jsn421942 Not many lotto plays with odds slightly better than a coin flip. Bought another 300K in OTC

@Likes2T Appreciate the response. No point in liquidating at this point. Worst case at this point is it just ends up helping my taxes next year.

$itrm Find a drug like this: All 3 PBM coverage, commercial traction, novel wonder-drug, global long lasting patents... that sold for less than $100M. You can't, Fishman failed. Let's hope cooler heads prevail with this bought-my-CEO-seat 🤡 on the sidelines.

$ITRM from the article below that mentions the recent 4 bankruptcies. One is not like the others (see below). There is a vacuum of de-risked, FDA approved quality assets available in this patent cliff M&A frenzied environment. fiercepharma.com/pharma/iterum-…

@jsn421942 A buyout will happen, whether it clears $60M is the question. Hiring a global powerhouse (who typically resolves complex multi billion deals) to handle the deal is telling. It isn’t over despite what the uninformed believe.

@Likes2T In your opinon, can a buy out still happen? I know it is now on OTC but I don't really see the point in liquidating to save my remaining 5%.

$itrm. Read the March 27th update on Iterum’s website. The specific line about withdrawing from the US business if a deal is not done soon. Teneo is the real deal. Effectively saying, “We will stop funding the existing US team immediately and it will cost you $150+ to resume

@clinicnerds Shionogi is a perfect fit with Japan’s AMR focus and subsidies (and Orlynvah’s patent).

@Likes2T Maybe pharma royalty companies are a good fit for Orlynvah: Innoviva, Royalty Pharma, Theravance ...

$ITRM using Gemini and ChatGPT, I asked for an unbiased ranking comparing all attributes against recent and similar drugs sold in liquidation or bankruptcy. You be the judge:

@clinicnerds Absolutely. By hiring Teneo they went full overkill. To me it implies there are dollars to be had above debt. Anything over ~$60M goes to equity.

@Likes2T Interesting comparison - maybe Innoviva will bid on Orlynvah. Can shareholders get anything in liquidation? How far down the capital structure are shareholders? There is a debt to Pfizer ($20m?), outstanding bills to Eversana and whoever manufactures Orlynvah for them.

$itrm Last day on the NASDAQ. Will this be the first full de-risked novel asset with early commercial traction to sell for <$100M? Is Fishman the worst CEO in biotech history? Time will tell in less than three weeks.

$itrm @HCWCO How is that $5-$9 price target doing? Surely even a failure of a CEO in Fishman can’t deter buyers…

$ITRM We all see the discord pump groups. In between the already 400M volume and 5 turns is the smart positions accumulating under the radar with no clues. Does this sell for more or less than $80M - $100M? Find another fully de-risked drug like this currently available...

@clinicnerds @Assholetrading @Twills08 Unless I’m wrong they don’t have ROFR, otherwise I doubt we would have two parties this far along. We need these two to be mid-sized plug and play suitors. The recipe is there for this liquidation sale to force competitive bids. You wont find another drug in this stage before.

@Assholetrading @Twills08 @Likes2T Maybe $PFE buys it back - plugs it into their global salesforce - over the next decade is multibagger - doesn't move the needle much but could help cover their nice dividend payout

$ITRM baffling - ceo/cfo resigned - wind down hearing is April 13 - if a company like Pfizer made a low-ball offer over the weekend does the Board of Dirs have the authority to agree to a deal? Any Irish corporate law experts? What/who is blocking a deal? @Twills08 @Likes2T

@clinicnerds Two bidders explicitly mentioned in the 8K. Mendoza line is $80M that leaves $25M+ to equity. 10x min from here unless some underhanded shenanigans are underway.

$ITRM positive spin If stock goes to $0 Board of Dirs knows they will be tied up for years in shareholder lawsuits without a company to pay legal fees - so they are motivated to get a deal done before bankruptcy Ceo resigned so Board can run a firesale

$ITRM I’ve seen garbage drugs not even FDA approved sell for $100M in bankruptcy. Orlynvah is the first of it’s kind novel oral carbapenem that has gained seismic traction in Q1 2026. They have extensive global patents (Japan, China, Mexico). Unreal situation & opp for buyer.

$itrm 20M AH volume. A lot of large blocks after retail flushed. Regardless how this ends, a big F you to Fishman. May karma find you fast

$itrm The CFO and CEO resigning are procedural after wind down and hand-off to liquidating firms. Not a bad thing having these two clowns out of the picture.

$ITRM Is this move 10 minutes ago what it appears to be? Very interesting.

@clinicnerds @Twills08 It’s procedural. Really suspect with two bidders at the table. Shows the corruption in bio tech.